



Council of the European Union
General Secretariat

Brussels, 18 March 2019

**Interinstitutional files:
2018/0018(COD)**

WK 3869/2019 INIT

**DOCUMENT PARTIALLY
ACCESSIBLE TO THE
PUBLIC (04.08.2022)**

LIMITE

PHARM
SAN
MI
COMPET
IA
CODEC

WORKING PAPER

This is a paper intended for a specific community of recipients. Handling and further distribution are under the sole responsibility of community members.

WORKING DOCUMENT

From: General Secretariat of the Council
To: Working Party on Pharmaceuticals and Medical Devices (HTA)
N° Cion doc.: 5844/18 PHARM 6 SAN 49 MI 61 COMPET 53 IA 43 CODEC 133 + ADD 1 +
ADD 2 + ADD3 + COR 1

Subject: Working Party on Pharmaceuticals and Medical devices on 25 March 2019
- Flash from the Presidency

Delegations will find enclosed the Presidency Flash for the meeting of the Working Party on Pharmaceuticals and Medical devices that will take place on 25 March 2019 (CM 2158/19)

FLASH

Working Party on Pharmaceuticals and Medical devices

25 March 2019, EB S3, 10.00
(CM 2158/19)

Dear Colleagues,

We have a full agenda for this meeting of the Working Party on Pharmaceuticals and Medical Devices: we will mainly discuss HTA, but we will also receive information on the selection procedure for the EMA Management Board and on competition enforcement in the pharmaceutical sector. We propose to start at 10:00 and finish at approximately 18:00.

As the first point we intend to discuss the revised text for Articles 12 to 18 that you can find in WK 3754/2019. The Presidency prepared it based on your comments from our last Working Party meeting. We hope to focus only on outstanding issues.

Then we intend to have the main discussion of the day on the Presidency proposals for Articles 24 to 28 in Chapter IV (Support Framework), which you can find in WK 3755/2019.

As a third point on our agenda, we hope to start a discussion on conflict of interests and transparency, supported by a revised text prepared by the Netherlands delegation, which should be sent out shortly.

The fourth point will be information from the Council Secretariat on the selection procedure for the EMA Management Board.

Last, but not least, at around 17:00, colleagues from DG Competition of the European Commission will present a report on enforcing competition in the pharmaceutical sector, followed by a discussion.

At our Working Party on 8 April we intend to discuss a revised text for Chapter IV (Support Framework), continue to discuss conflict of interests and transparency issues and start the discussion on the structure of the Coordination Group.

In case there are any points that you would like to raise under AOB, we kindly invite you to inform the Presidency (presedintie.sanatate@ms.ro) and the Council Secretariat in advance (life.pharmaceuticals@consilium.europa.eu).

The Romanian Presidency health team,

DELETED

DELETED
DELETED
DELETED@rpro.eu

DELETED
DELETED
DELETED@rpro.eu

